← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Drugs for urinary frequency and incontinence
fesoterodine
G04BD11
Forms & Strengths
- Extended-release tablets: 4mg, 8mg
- Film-coated tablets
Adult Dosing
- 4mg orally once daily, may increase to 8mg orally once daily
- Dose adjustment for renal impairment: 4mg orally once daily for CrCl 30-59 mL/min, not recommended for CrCl <30 mL/min
- Dose adjustment for hepatic impairment: 4mg orally once daily for mild impairment, not recommended for moderate or severe impairment
Pediatric Dosing
- Safety and efficacy not established in patients <18 years old
Indications
- Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency
Mechanism of Action
- Competitive muscarinic receptor antagonist, decreases bladder contractility and increases bladder capacity
Contraindications
- Hypersensitivity to fesoterodine or tolterodine
- Urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma
- Severe hepatic impairment (Child-Pugh C)
- Severe renal impairment (CrCl <30 mL/min) or patients requiring hemodialysis
Adverse Reactions
- Dry mouth, constipation, urinary retention, dyspepsia, abdominal pain, dizziness,somnolence, blurred vision, heat stroke in patients at risk
Drug Interactions
- Increased risk of anticholinergic effects with other muscarinic receptor antagonists, concurrent use not recommended
- CYP3A4 inhibitors may increase fesoterodine exposure, monitor for adverse reactions
- Inducers of CYP3A4 may decrease fesoterodine exposure, monitor for decreased efficacy
Curated Content: Needs Vetting Before Put to Clinical Use